One of the new and exciting prospects in the treatment of glaucoma is called MIGS, or Minimally Invasive Glaucoma Surgeries. These procedures are exciting from a patient’s perspective because they are generally safer with quicker recovery times.One of the new and exciting prospects in the treatment of glaucoma is called MIGS, or Minimally Invasive Glaucoma Surgeries. These procedures are exciting from a patient’s perspective because they are generally safer with quicker recovery times.
What are MIGS?
Before discussing specific MIGS procedures, it would be helpful to define what constitutes “MIGS.” There are quite a few definitions of MIGS, but the American Glaucoma Society, which is the largest society of glaucoma specialists in the United States, provides the following working definition:
- IOP, or intraocular pressure, should be lowered by improving outflow of eye fluid. This is the same mechanism used by traditional glaucoma surgeries, such as trabeculectomy or tube shunt surgeries.
- The device or procedure can either be approached from inside the eye (ab-interno) or outside the eye (ab-externo). As an example, both trabeculectomy and tube shunt procedures are performed from outside the eye, or an ab-externo approach. MIGS procedures using an approach from inside of the eye are described below in the iStent and Trabectome sections.
- There should be limited surgical manipulation of the sclera, which is the thick white wall of the eye. Trabeculectomy involves quite a bit of extensive cutting of the sclera, and that includes trabeculectomy modified with the Ex-PRESS shunt surgeries.
- MIGS should have little manipulation of the conjunctiva, which is the transparent outermost layer of the eye. By contrast, non-MIGS procedures, such as trabeculectomy and tube shunt procedures involve extensive cutting of the conjunctiva.
In meeting these criteria, MIGS procedures do not preclude the possibility of future, more traditional surgical approaches, such as trabeculectomy or tube shunt surgery.
There have been a plethora of abstracts, presentations, papers in recent years detailing the use of MIGS procedures. However, there is still a lack of consensus, even among clinical trials, as to what constitutes a MIGS device, which patients are most appropriately suited for these procedures, and what constitutes surgical success. The purpose of this article is not to provide an exhaustive or comprehensive list and details about all of the FDA approved and not yet approved MIGS procedures that are under development, but to give patients an overview of the MIGS procedures and some questions you will want to ask your ophthalmologist to find out if a MIGS procedure is right for you.
Overall, MIGS procedures have been touted as safer than our traditional trabeculectomy or tube shunt surgeries. This is because they do not have some of the associated complications from trabeculectomy and tube shunt procedures, such as low eye pressure (hypotony) and bleb infection. However, doctors do not yet have long-term safety or effectiveness data. Currently, there are also no randomized clinical trials comparing MIGS procedures to the “gold standard” procedure of trabeculectomy.
Shorter Surgery Time
Many of the MIGS procedures involve implantation of small devices. MIGS procedures are generally faster than trabeculectomy and tube shunt surgeries, and shortened surgical time can be very important for the safety of the patient. Many MIGS procedures are combined with cataract surgery, adding a short amount of time to the total surgical procedure. This is an important point to understand as well, since many clinical trials will compare a MIGS procedure combined with cataract surgery to cataract surgery alone.
Lowering of Eye Pressure
Lastly, an important point is that the majority of MIGS procedures are safer than trabeculectomy, but they are also not as effective in lowering eye pressure. The eye pressure in the majority of MIGS clinical trials is typically in the mid-teens range (approximately 15). Many ophthalmologists do not think MIGS procedures are appropriate for patients who have advanced glaucoma and need much lower eye pressures.
To start off a discussion of some of the currently FDA approved MIGS procedures, the Trabectome (also called trabeculectomy ab-interno) will be described, which was FDA approved in 2006. The Trabectome is an electrocautery device that removes part of the trabecular meshwork, exposing the outflow channels of the eye and thereby lowering eye pressure. The trabecular meshwork constitutes part of the drainage system of the eye, and typically is impaired in glaucoma patients causing eye pressure to increase. The Trabectome procedure is quick and can be combined with cataract surgery. The safety profile is quite good, with the most common complication being some blood in the front of the eye after the procedure. This complication is typically limited and clears fairly quickly; however, scarring can occur over the treated area, thereby limiting the effectiveness of the Trabectome method. Furthermore, as with most MIGS procedures, the eye pressure lowering effect is limited to the mid-teens.
More recently, the FDA has approved the use of the iStent, which is the smallest implantable device approved for use in the human body. It is a titanium device that is implanted from inside of the eye (an ab interno approach) into the trabecular meshwork in order to bypass it and improve outflow of eye fluid. iStents are typically implanted during the time of cataract surgery, and in some cases more than one iStent is implanted. Again, the benefit of iStent is its higher safety profile, but the downside is that it does not lower eye pressure to the same extent as trabeculectomy. As with other MIGS procedures, iStent typically lowers eye pressure to the mid-teens.
There are many more MIGS devices and procedures that are in clinical trials but not yet FDA approved. It does seem that the landscape for glaucoma patients is changing. The general consensus is that MIGS may be appropriate for patients who have mild to moderate glaucoma, who are intolerant of or noncompliant with eye pressure lowering drops, who do not require a very low target eye pressure, and who are undergoing cataract surgery. Because these procedures are so new, it is hard to predict exactly where MIGS will fit in to the glaucoma treatment landscape. But it is an exciting time for the field as these new technologies develop and come to market.
Questions to Ask Your Eye Doctor
- How many of these procedures have you performed?
- This question should be asked with the understanding that these procedures are quite new. While there is a learning curve in adopting any new surgical technique, MIGS procedures are designed to be quick and less complicated in terms of the number of steps required, and ophthalmologists are very adept at intraocular surgery.
- What is your personal experience with MIGS procedures?
- Do you have a financial interest in the company that produces the MIGS device or are there any other conflicts of interest?
- Would you personally undergo this procedure or recommend a family member to have it?
This content was last updated on: Monday, May 5, 2014
The information provided here is a public service of the BrightFocus Foundation and should not in any way substitute for personalized advice of a qualified healthcare professional; it is not intended to constitute medical advice. Please consult your physician for personalized medical advice. BrightFocus Foundation does not endorse any medical product or therapy. All medications and supplements should only be taken under medical supervision. Also, although we make every effort to keep the medical information on our website updated, we cannot guarantee that the posted information reflects the most up-to-date research.
These articles do not imply an endorsement of BrightFocus by the author or their institution, nor do they imply an endorsement of the institution or author by BrightFocus.
Some of the content may be adapted from other sources, which will be clearly identified within the article.